Regorafenib Resistance | List of Frontiers open access articles

Original Research

Published on 24 Jun 2020

Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

in Pharmacology of Anti-Cancer Drugs

Weiwei Shi
Shan Zhang
Ding Ma
Dongliang Yan
Guang Zhang
Yin Cao
Zhongxia Wang
Junhua Wu
Chunping Jiang

Frontiers in Oncology

doi 10.3389/fonc.2020.00694

7,781 views
46 citations

Original Research

Published on 11 Aug 2021

Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7

in Signaling

Mustafa Karabicici
Yagmur Azbazdar
Gunes Ozhan
Serif Senturk
Zeynep Firtina Karagonlar
Esra Erdal

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.639779

10,681 views
51 citations

Original Research

Published on 13 Nov 2024

EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma

in Hepatobiliary Diseases

Lili Hu
Weiwei Shi
Kua Liu
Ding Ma
Qilei Xin
Zhongxia Wang
Yin Cao
Guang Zhang

Frontiers in Medicine

doi 10.3389/fmed.2024.1464610

2,586 views
7 citations

Original Research

Published on 05 Mar 2020

Long Non-coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

in Cancer Molecular Targets and Therapeutics

Fang Wei
Mofei Wang
Zhen Li
Yong Wang
Yong Zhou

Frontiers in Oncology

doi 10.3389/fonc.2020.00291

5,243 views
7 citations

Original Research

Published on 23 Jul 2025

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids

in Cancer Cell Biology

Giulia Agostini
Morgane Leprovots
Jérôme Jeandriens
Anne Lefort
Frédérick Libert
Francesco Sclafani
Ingrid Langer
Alain Hendlisz
Marie-Isabelle Garcia

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2025.1631116

3,174 views
1 citation

Original Research

Published on 17 Jun 2021

Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs

in Pharmacology of Anti-Cancer Drugs

Kunyuan Wang
Ganxiang Yu
Jiaen Lin
Zhilei Wang
Qianting Lu
Chengxin Gu
Tao Yang
Shiming Liu
Hui Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2021.632201

4,703 views
13 citations

Correction

Published on 07 Jan 2022

Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

in Cancer Molecular Targets and Therapeutics

Fang Wei
Mofei Wang
Zhen Li
Yong Wang
Yong Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.818876

2,188 views

Articles

Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma

Changes in Wnt and TGF-β Signaling Mediate the Development of Regorafenib Resistance in Hepatocellular Carcinoma Cell Line HuH7

EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma

Long Non-coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling

Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids

Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs

Corrigendum: Long Non-Coding RNA MIR570MG Causes Regorafenib Resistance in Colon Cancer by Repressing miR-145/SMAD3 Signaling